Spastic Paraplegia 20 (Troyer Syndrome) (SPG20) (N-Term) Peptide
Our Local Distributor
北京 101111
Quick Overview for Spastic Paraplegia 20 (Troyer Syndrome) (SPG20) (N-Term) Peptide (ABIN5673676)
抗原
宿主
资源
应用范围
-
-
蛋白结构域
- N-Term
-
序列
- MEQEPQNGEP AEIKIIREAY KKAFLFVNKG LNTDELGQKE EAKNYYKQGI
-
产品特性
- This is a synthetic peptide designed for use in combination with anti- SPG20 Antibody. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
-
-
-
-
应用备注
- Optimal working dilution should be determined by the investigator.
-
限制
- 仅限研究用
-
-
-
状态
- Lyophilized
-
溶解方式
- Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
-
储存条件
- -20 °C
-
储存方法
- For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
-
-
- SPG20 (Spastic Paraplegia 20 (Troyer Syndrome) (SPG20))
-
背景
-
This gene encodes a protein containing a MIT (Microtubule Interacting and Trafficking molecule) domain, and is implicated in regulating endosomal trafficking and mitochondria function. The protein localizes to mitochondria and partially co-localizes with microtubules. Stimulation with epidermal growth factor (EGF) results in protein translocation to the plasma membrane, and the protein functions in the degradation and intracellular trafficking of EGF receptor. Multiple alternatively spliced variants, encoding the same protein, have been identified. Mutations associated with this gene cause autosomal recessive spastic paraplegia 20 (Troyer syndrome).
Alias Symbols: SPARTIN, TAHCCP1
Protein Size: 666 -
基因ID
- 23111
-
NCBI登录号
- NM_001142294, NP_001135766
-
UniProt
- Q8N0X7
抗原
-